News & Updates
Filter by Specialty:
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022
Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022
Fixed-dose albuterol/budesonide an effective rescue med in moderate-to-severe asthma
15 Jun 2022
byRoshini Claire Anthony
A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.